NASDAQ losers: Supertel Hospitality Inc (NASDAQ:SPPR), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Uranium Resources, Inc. (NASDAQ:URRE), Tesco Corporation (USA) (NASDAQ:TESO), Hyperion Therapeutics Inc (NASDAQ:HPTX)

Supertel Hospitality Inc (NASDAQ:SPPR) announced the results of its previously announced offering of subscription rights to purchase shares of its common stock, par value $0.01 per share. Pursuant to the rights offering, subscription rights to purchase approximately 1.77 million shares of common stock were exercised, resulting in gross proceeds to Supertel of approximately $2.8 million. Supertel Hospitality Inc (NASDAQ:SPPR) net profit margin is -15.00% and weekly performance is -2.50%. On last trading day company shares ended up $1.56. Analysts mean target price for the company is $2.00. Supertel Hospitality Inc (NASDAQ:SPPR) distance from 50-day simple moving average (SMA50) is -4.88%.

On 22 MAY Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced that the company will soon present at the Jefferies 2014 Global Healthcare Conference in New York. Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares fell -5.22% in last trading session and ended the day on $20.88. MRTX return on assets is -169.70%. Mirati Therapeutics, Inc. (NASDAQ:MRTX) quarterly performance is -0.14%.

On 6 JUNE Uranium Resources, Inc. (NASDAQ:URRE) announced that its long-serving Chairman Paul K. Willmott has turned over his role to fellow Director Terence J. Cryan, following the Company’s Annual Meeting of Stockholders. Mr. Willmott served the Company for the past 19 years either on the Board as Chairman or as Chief Executive Officer, and will remain on the Board. Uranium Resources, Inc. (NASDAQ:URRE) shares moved down -5.13% in last trading session and was closed at $2.59, while trading in range of $2.54 – $2.74. Uranium Resources, Inc. (NASDAQ:URRE) year to date (YTD) performance is -14.52%.

On 22 MAY Tesco Corporation (USA) (NASDAQ:TESO) reported $0.21 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.25 by $0.04. The company had revenue of $121.40 million for the quarter, compared to the consensus estimate of $137.52 million. During the same quarter last year, the company posted $0.22 earnings per share. Tesco Corp.’s revenue was down 4.5% compared to the same quarter last year. Analysts expect that Tesco Corp. will post $1.19 EPS for the current fiscal year. Tesco Corporation (USA) (NASDAQ:TESO) ended the last trading day at $21.27. Company weekly volatility is calculated as 3.06% and price to cash ratio as 8.33. Tesco Corporation (USA) (NASDAQ:TESO) showed a positive weekly performance of 1.72%.

On 3 JUNE Hyperion Therapeutics Inc (NASDAQ:HPTX) announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Standard review in Canada takes 18 months or more and Priority Review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review time to approximately six months. Hyperion Therapeutics Inc (NASDAQ:HPTX) net profit margin is 44.20% and weekly performance is -9.75%. On last trading day company shares ended up $26.00. Analysts mean target price for the company is $39.20. Hyperion Therapeutics Inc (NASDAQ:HPTX) distance from 50-day simple moving average (SMA50) is 1.14%.